About us

The Phase II trial of ENERGI-F703 Diabetic Foot Ulcer Gel meets the primary endpoint. Energenesis is planning phase III clinical trials

Results of the double-blinded, randomized US/Taiwan phase II trial of ENERGI-F703 show that ENERGI-F703 gel significantly improves the complete closer rate versus placebo in patients with Wagner grading 1 to 2 diabetic foot ulcers.